Photocure's Platform Pivot: Bladder Cancer Diagnostics Powerhouse
Core Cysview growth accelerates while management doubles down on precision diagnostics and AI
PHO.OL · Earnings Call · 2026-07-29
A Quarter of Contradictions
Photocure reported another robust quarter of core business growth, yet the headline numbers tell a two-sided story. Hexvix/Cysview product revenue rose 11% at constant currency, with North America up 12% and Europe up 10%, as CEO Daniel Schneider emphasized: “Overall, we had 11% product revenue growth ex FX.” — Daniel Schneider, President and CEO · 2026-07-29 Adjusted EBITDA came in at NOK 27.2 million, roughly flat year-over-year, while reported EBITDA was negative NOK 2 million. The gap is entirely explained by aggressive investment in strategic initiatives, including business development expenses of NOK 21.8 million and the Vesica Health acquisition. CFO Dick Peters clarified the metric: “Adjusted EBITDA, which excludes milestones, business development expenses and other certain ad hoc or noncash expenses came in at NOK 27.2 million.” — Dick Peters, Vice President of Finance and IT · 2026-07-29 This is a company deliberately trading short-term profitability for long-term platform building. The core franchise continues to muscle forward—the installed base of Saphira towers grew, ForTec mobile rentals expanded, and active U.S. accounts jumped 20% year-over-year. But the real story is the transformation from a single product company into a broader bladder cancer precision diagnostics platform.From Single Product to Platform
The Vesica Health acquisition closed in June, adding AssureMDx, a urine-based biomarker test that sits upstream of cystoscopy. Management argues this is exactly the right adjacency: identifying high-risk patients earlier funnels more appropriate procedures to blue light cystoscopy. Schneider was emphatic about the asset's quality: “It is best of class in terms of sensitivity, specificity and negative predictive value and area under the curve. I mean, quite frankly, there are other assets out there. This is the best one by far” — Daniel Schneider, President and CEO · 2026-07-29. The acquisition aligns with addressable market expansion; Photocure currently serves less than 10% of the potential U.S. market. With flexible cystoscopy (the future Flex system) and the biomarker test, the total opportunity multiples overnight. Complementing the acquisition is the partnership with Artera AI, monetizing Photocure's blue light registry with digital pathology AI. The company is building a portfolio of tools that span detection, surveillance, and treatment monitoring. As Schneider put it: "We believe by adding Vesica Health, partnerships with Artera, Convergent, AI, blue light cystoscopy, flexible scope with Richard Wolf, we're well on our way of establishing ourselves as the company of choice and the products of choice for bladder cancer care" (component 1789083700716461073). This is a clear departure from the prior narrative, where the company was reliant on OEM partners and a single drug-device combo.Regulatory Catalysts and the Medicare reimbursement Overhang
The biggest near-term catalyst is the FDA's reclassification of blue light cystoscopy equipment, which could dramatically expand the market access for the technology. Schneider noted the FDA has confirmed it will begin the process in H2 2026, and he is optimistic about the timeline: “the FDA has confirmed they will begin the reclass in the second half of this year. That press release was approved by the FDA.” — Daniel Schneider, President and CEO · 2026-07-29 This is a reiteration, but the urgency has increased—two OEMs are already petitioning through alternative pathways, and the company is preparing for a more competitive U.S. landscape. The long-term growth guidance of >25% CAGR through 2030 is predicated on these catalysts unlocking the surveillance market, which is 2-3x the current OR-based market. However, the reimbursement picture for AssureMDx remains the key swing factor. The company expects initial revenue in 2027 ahead of formal Medicare reimbursement by mid-2028, relying on early access programs and commercial lab pathways. This is a calculated bet: the molecule diagnostics business has attractive 30%+ EBITDA margins at scale, but it also carries execution risk in a regulatory and reimbursement maze.Asieris Arbitration: A Legal Overhang
One sour note is the arbitration with Asieris. Photocure has initiated legal steps to recover outstanding milestone payments related to the China approval and EMA submission. Schneider attempted to strike an optimistic tone: “We feel like we're in a very strong position.” — Daniel Schneider, President and CEO · 2026-07-29 But the dispute could delay or jeopardize a portion of the partnership's economics, which are already counted in Photocure's financials. This is a new and unresolved issue that investors will watch closely.The core business is executing, the strategic pivot is well-reasoned, but the path to profitability now hinges on a string of regulatory and reimbursement achievements. Photocure is a story of disciplined investment, but the market will demand evidence that these catalysts convert into cash flow. The company has a solid balance sheet (NOK 162.4M cash, no debt) to fund the journey, but the clock is ticking.With Vesica, we now expect the consolidated company to deliver revenue growth above 25% annually from 2026 through 2030, while maintaining strong profitability and targeting adjusted EBITDA margins above 25% by 2030.